JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online June 12, 2009, 10.2967/jnumed.108.056812
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
jnumed.108.056812v1
50/7/1178    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harris, D. A.
Right arrow Articles by Parseghian, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harris, D. A.
Right arrow Articles by Parseghian, M. H.
Journal of Nuclear Medicine Vol. 50 No. 7 1178-1186
© 2009 by Society of Nuclear Medicine
doi: 10.2967/jnumed.108.056812

Basic Science Investigation

In-Line Radiolabeling: A Novel Continuous-Flow System for Commercial-Scale Protein Labeling

Debra A. Harris1, Raimo Pellikka2, Olga Gasser2, Peter Blaeuenstein2, Robert Waibel2, P. August Schubiger2,3, Steven W. King1 and Missag H. Parseghian1

1 Research and Development, Peregrine Pharmaceuticals Inc., Tustin, California; 2 Center for Radiopharmaceutical Science, Paul Scherrer Institute, Villigen, Switzerland; and 3 Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, Zurich, Switzerland

Correspondence: For correspondence or reprints contact: Missag H. Parseghian, Research and Development, Peregrine Pharmaceuticals Inc., 14272 Franklin Ave., Tustin, CA 92780. E-mail: mparseghian{at}peregrineinc.com

A key limitation in developing radiotherapeutic proteins is the expense of manufacturing the drug in small batches using traditional reaction vessels. Removing limitations on the quantity of protein labeled at any one time significantly decreases the cost of production, and nowhere is the need for cost-effective radiotherapeutics more acute than in the treatment of cancer. Methods: We describe a novel method that can rapidly radiolabel, theoretically, unlimited amounts of protein, without causing significant damage to binding potency or structural integrity. Our process controls the reaction rate for the isotope and reactants as they simultaneously flow through a reaction tube. Results: We have demonstrated proof of principle by labeling nearly a gram of antibody with 481 GBq (13 Ci) of 131I during a single 30-min reaction run. Conclusion: Simple to construct, our system is already used to manufacture a radiolabeled antibody, both in the United States and in India, as part of clinical trials to treat glioblastoma multiforme. Modified, this system may be also applicable for nonradioactive labeling.

Key Words: radiolabeling • protein labeling • nuclear medicine • radiotherapeutic antibodies • glioblastoma multiforme

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2009 by the Society of Nuclear Medicine.